- Home
- BALL vs EXEL Comparison
BALL vs EXEL Comparison
Compare BALL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BALL | EXEL |
|---|---|---|
| Founded | 1880 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 14.0B |
| IPO Year | 2009 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BALL | EXEL |
|---|---|---|
| Price | $63.25 | $55.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $69.00 | $46.50 |
| AVG Volume (30 Days) | 2.4M | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 0.77 | ★ 0.79 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $7.96 | $13.61 |
| Revenue Next Year | $3.51 | $13.13 |
| P/E Ratio | $80.84 | ★ $70.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.83 | $33.76 |
| 52 Week High | $68.56 | $57.57 |
Technical Indicators
Market Signals| Indicator | BALL | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 58.74 |
| Support Level | $56.85 | $40.77 |
| Resistance Level | $63.47 | $57.57 |
| Average True Range (ATR) | 1.53 | 1.41 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 73.92 | 60.20 |
Price Performance
Historical ComparisonAbout BALL Ball Corporation
Ball is the world's largest metal can manufacturer with market share over 30% in its three main regions (North America, Europe, and South America). The company is focused on increasing capacity amid a wave of new developed-market demand, while also investing in faster-growing emerging-market economies. Ball spun-off its glass jar business in 1993 and is now owned by Newell. The company reports three segments—beverage packaging, North and Central America (48% of 2025 revenue), beverage packaging, EMEA (30%), beverage packaging, South America (16%)—and it generated $13 billion in revenue in 2025.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.